What we are studying
The purpose of this research study is to compare the effects (good and bad) of pembrolizumab given in combination with low-dose paclitaxel. The drug pembrolizumab is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells. Pembrolizumab had been approved for the treatment of melanoma and is being studied for the treatment of patients with other cancers including urothelial carcinoma. Paclitaxel is already a standard chemotherapy treatment for urothelial carcinoma. The goal of this study is to determine if paclitaxel can improve the anti-tumor activity of pembrolizumab.
Parking validation for study visits